Burden of Herpes Zoster Among People with Human Immunodeficiency Virus in the United States

Clicks: 4
ID: 338354
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #316 of 318 articles by views in Open forum infectious diseases

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 318 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background Recent United States data on incidence, healthcare resource utilization (HRU), and costs for herpes zoster (HZ) in adults with human immunodeficiency virus (HIV) are lacking. Methods This retrospective cohort study included insured adults during 2015–2022. HZ incidence rates were estimated among HZ-unvaccinated adults with HIV, HIV without other immunocompromising conditions (ICC) (HIV only), and 1,000,000 randomly selected adults with no ICC. Poisson regression was used to estimate adjusted incidence rate ratios (aIRRs) and 95% confidence intervals (CIs). All-cause HRU and costs were compared between propensity score-matched cohorts with HIV and HZ versus HIV without HZ during the first 1, 3, and 12 months after an episode of HZ. Results The incidence rates of HZ in the HIV (n = 53,700), HIV only (n = 41,544), and no ICC cohorts were 12.0, 10.3, and 5.6 per 1,000 person-years, respectively (HIV vs. no ICC: aIRR 2.05, 95% CI 1.92–2.19; HIV only vs. no ICC: aIRR 1.93, 95% CI 1.79–2.09). Mean all-cause per-patient costs were higher among adults with HIV and HZ during the first month (n = 1,078 and 4,312; cost difference $3,075, 95% CI $1,239–4,911) and the first 3 months (n = 994 and 3,976; $2,980, 95% CI $649–5,310) compared with adults with HIV without HZ. Conclusions People with HIV are at increased risk of HZ compared to adults without ICC, and the costs associated with HZ among people with HIV are considerable. These findings support the importance of HZ prevention for adults with HIV.
Reference Key
openalex_W7225195198 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Nikita Stempniewicz, Andrea Steffens, Kimvi Kim, Mary DuCharme, Zhu Yong, Stephanie J Gallagher, Rajeev B. Shah, Cindy P. Garris, David Singer
Are you one of these authors? Claim your profile
Journal Open forum infectious diseases
Year 2026
DOI
10.1093/ofid/ofag702
URL
https://doi.org/10.1093/ofid/ofag702
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.